Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence
Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Methods Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Ital...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 60; no. 5; pp. 2456 - 2460 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
14.05.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1462-0324 1462-0332 1462-0332 |
DOI | 10.1093/rheumatology/keaa454 |
Cover
Abstract | Abstract
Objectives
To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.
Methods
Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient’s characteristics in the 2018–2019 influenza season.
Results
Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018–2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65–74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75–84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.
Conclusion
Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients. |
---|---|
AbstractList | To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.
Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.
Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.
Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients. To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.OBJECTIVESTo verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.METHODSAdministrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.RESULTSOverall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.CONCLUSIONInfluenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients. Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Methods Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient’s characteristics in the 2018–2019 influenza season. Results Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018–2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65–74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75–84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence. Conclusion Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients. |
Author | Valent, Francesca De Vita, Salvatore Quartuccio, Luca Zabotti, Alen Gallo, Tolinda |
Author_xml | – sequence: 1 givenname: Luca orcidid: 0000-0002-0134-6439 surname: Quartuccio fullname: Quartuccio, Luca email: luca.quartuccio@asufc.sanita.fvg.it organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine – sequence: 2 givenname: Alen orcidid: 0000-0002-0573-464X surname: Zabotti fullname: Zabotti, Alen organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine – sequence: 3 givenname: Tolinda surname: Gallo fullname: Gallo, Tolinda organization: Department of Prevention, Azienda sanitaria universitaria Friuli Centrale – sequence: 4 givenname: Salvatore surname: De Vita fullname: De Vita, Salvatore organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine – sequence: 5 givenname: Francesca surname: Valent fullname: Valent, Francesca organization: Institute of Epidemiology, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33083815$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU2LFDEQhoOsuB_6D0Ry9DJOOklPp_cmix8LC170HKrTlZloJ2nzsTD7C_zZ9jizIl70UFRRvM8bUu8lOQsxICEvG_amYb1Ypx1WDyVOcbtff0MA2con5KKRG75iQvCz3zOX5-Qy56-MsbYR6hk5F4IpoZr2gvy4DXaqGB6A3oMxLkBxMVAXqNmlGJxZRjuBP7yU9hRS2SVXXKY1jJi20YUtdd7XEHOd54Q5u3ukJSEUj6Hka1rQzzHBdFiGkcJSFszilmm0FMYdLnuDz8lTC1PGF6d-Rb68f_f55uPq7tOH25u3dyvDe9WueC8ZR2M60Yrejhu7_EOpFhtoN80gZaeQSW7sYJWyDIQUOAAzY6eEGDYDiivy-ug7p_i9Yi7au2xwmiBgrFlz2fK-Ux1vFumrk7QOHkc9J-ch7fXj9RbB9VFgUsw5odXGlV8HLAncpBumD1HpP6PSp6gWWP4FP_r_A1sfsVjn_yN-AuoKtC4 |
CitedBy_id | crossref_primary_10_1016_j_jaut_2022_102827 crossref_primary_10_1186_s12969_024_01048_1 |
Cites_doi | 10.1093/rheumatology/keaa078 10.1086/341403 10.3389/fmicb.2020.00135 10.1016/j.semarthrit.2015.01.002 10.2174/1871528114666160105113046 10.1136/ard.2011.152983 10.1136/annrheumdis-2019-215882 10.1093/rheumatology/kes305 10.1016/j.jare.2018.09.003 10.3899/jrheum.181376 10.1016/j.ajic.2010.04.210 10.1093/rheumatology/key156 10.1080/03009742.2016.1242774 10.1002/acr.22246 10.1371/journal.pone.0153848 10.1136/fmch-2019-000198 10.1016/j.vaccine.2015.01.065 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1093/rheumatology/keaa454 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
EndPage | 2460 |
ExternalDocumentID | 33083815 10_1093_rheumatology_keaa454 10.1093/rheumatology/keaa454 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 KAQDR KBUDW KC5 KOP KQ8 KSI KSN L7B M-Z M49 MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RHF RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 AAYXX ABDFA ABEJV ABGNP ABVGC ADNBA AEMQT AGORE AHGBF AHMMS AJBYB AJNCP ALXQX CITATION JXSIZ NPM 7X8 |
ID | FETCH-LOGICAL-c2985-29402ecc73539fd6f838885e1a561b4478e042cfbf88f0a343eba0cd7833b6be3 |
ISSN | 1462-0324 1462-0332 |
IngestDate | Thu Jul 10 17:52:29 EDT 2025 Thu Apr 03 07:09:33 EDT 2025 Tue Jul 01 04:04:19 EDT 2025 Thu Apr 24 23:16:11 EDT 2025 Wed Aug 28 03:18:56 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | influenza vaccine arthritis biologic agent small molecules |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2985-29402ecc73539fd6f838885e1a561b4478e042cfbf88f0a343eba0cd7833b6be3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-0573-464X 0000-0002-0134-6439 |
PMID | 33083815 |
PQID | 2452978721 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_2452978721 pubmed_primary_33083815 crossref_citationtrail_10_1093_rheumatology_keaa454 crossref_primary_10_1093_rheumatology_keaa454 oup_primary_10_1093_rheumatology_keaa454 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-May-14 |
PublicationDateYYYYMMDD | 2021-05-14 |
PublicationDate_xml | – month: 05 year: 2021 text: 2021-May-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2021 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Valent (2021051418595857600_keaa454-B8) 2019; 7 Charlotte (2021051418595857600_keaa454-B10) 2014; 66 Toussirot (2021051418595857600_keaa454-B16) 2016; 14 Lawson (2021051418595857600_keaa454-B13) 2015; 44 Nakafero (2021051418595857600_keaa454-B5) 2018; 57 (2021051418595857600_keaa454-B9) 2020 Nakafero (2021051418595857600_keaa454-B3) 2020 Rizzo (2021051418595857600_keaa454-B14) 2016 Qendro (2021051418595857600_keaa454-B7) 2020; 47 Ribeiro (2021051418595857600_keaa454-B19) 2011; 70 Quartuccio (2021051418595857600_keaa454-B4) 2018; 15 Spila Alegiani (2021051418595857600_keaa454-B15) 2017 Vogel (2021051418595857600_keaa454-B1) 2020; 11 Hak (2021051418595857600_keaa454-B12) 2002; 35 Furer (2021051418595857600_keaa454-B2) 2020; 79 Listing (2021051418595857600_keaa454-B20) 2013; 52 Nguyen (2021051418595857600_keaa454-B6) 2017; 46 Costello (2021051418595857600_keaa454-B18) 2016; 11 Maurer (2021051418595857600_keaa454-B11) 2010; 38 Hmamouchi (2021051418595857600_keaa454-B17) 2015; 33 |
References_xml | – year: 2020 ident: 2021051418595857600_keaa454-B3 article-title: Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keaa078 – volume: 35 start-page: 370 year: 2002 ident: 2021051418595857600_keaa454-B12 article-title: Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations publication-title: Clin Infect Dis doi: 10.1086/341403 – year: 2020 ident: 2021051418595857600_keaa454-B9 – volume-title: Stima dell’efficacia di campo del vaccino antinfluenzale, in Italia: stagioni 2010–2011 e 2011–2012 year: 2016 ident: 2021051418595857600_keaa454-B14 – volume: 11 start-page: 135 year: 2020 ident: 2021051418595857600_keaa454-B1 article-title: Broadly protective strategies against influenza viruses: universal vaccines and therapeutics publication-title: Front Microbiol doi: 10.3389/fmicb.2020.00135 – volume: 44 start-page: 666 year: 2015 ident: 2021051418595857600_keaa454-B13 article-title: Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2015.01.002 – volume: 14 start-page: 94 year: 2016 ident: 2021051418595857600_keaa454-B16 article-title: Vaccination and induction of autoimmune diseases publication-title: Inflamm Allergy Drug Targets doi: 10.2174/1871528114666160105113046 – volume: 70 start-page: 2144 year: 2011 ident: 2021051418595857600_keaa454-B19 article-title: Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice publication-title: Ann Rheum Dis doi: 10.1136/ard.2011.152983 – volume: 79 start-page: 39 year: 2020 ident: 2021051418595857600_keaa454-B2 article-title: 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-215882 – volume: 52 start-page: 53 year: 2013 ident: 2021051418595857600_keaa454-B20 article-title: The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment publication-title: Rheumatology (Oxford doi: 10.1093/rheumatology/kes305 – year: 2017 ident: 2021051418595857600_keaa454-B15 – volume: 15 start-page: 87 year: 2018 ident: 2021051418595857600_keaa454-B4 article-title: Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data publication-title: J Adv Res doi: 10.1016/j.jare.2018.09.003 – volume: 47 start-page: 770 year: 2020 ident: 2021051418595857600_keaa454-B7 article-title: Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care publication-title: J Rheumatol doi: 10.3899/jrheum.181376 – volume: 38 start-page: 489 year: 2010 ident: 2021051418595857600_keaa454-B11 article-title: Awareness of government seasonal and 2009 H1N1 influenza vaccination recommendations among targeted US adults: the role of provider interactions publication-title: Am J Infect Control doi: 10.1016/j.ajic.2010.04.210 – volume: 57 start-page: 1726 year: 2018 ident: 2021051418595857600_keaa454-B5 article-title: Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/key156 – volume: 46 start-page: 446 year: 2017 ident: 2021051418595857600_keaa454-B6 article-title: Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA) publication-title: Scand J Rheumatol doi: 10.1080/03009742.2016.1242774 – volume: 66 start-page: 1016 year: 2014 ident: 2021051418595857600_keaa454-B10 article-title: Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.22246 – volume: 11 start-page: e0153848 year: 2016 ident: 2021051418595857600_keaa454-B18 article-title: Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: a retrospective cohort study using data from the clinical practice research datalink publication-title: PLoS One doi: 10.1371/journal.pone.0153848 – volume: 7 start-page: e000198 year: 2019 ident: 2021051418595857600_keaa454-B8 article-title: Glycaemic control, antidiabetic medications and influenza vaccination coverage among patients with diabetes in Udine, Italy publication-title: Fam Med Community Health doi: 10.1136/fmch-2019-000198 – volume: 33 start-page: 1446 year: 2015 ident: 2021051418595857600_keaa454-B17 article-title: Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort publication-title: Vaccine doi: 10.1016/j.vaccine.2015.01.065 |
SSID | ssj0005138 |
Score | 2.3413663 |
Snippet | Abstract
Objectives
To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing... To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2456 |
Title | Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33083815 https://www.proquest.com/docview/2452978721 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiPeWl4zEAWmV3SR2HIcb4rELYjlAF1VcIsdxaMWSrLpNhfYX8BP5OYwfSVyKYJdL1Frp5DFfPePxNzMIPakYiSWjSaAkkwGtVBhkYSYDQrKoLEgpUqnjkIfv2cERfTtNpqPRT4-11C6LXXn2x7yS_9EqjIFedZbsBTTbC4UB-Az6hSNoGI7n0vEb22HkTOyshJRzG9jTEQxpS95qqhVo_JvdSQcBM1PCyPS-XXxpTDqLzg9pTtsTS4hdqYF6bshyrnSVYaTbsq59ix7DIJjZdEHfx_0wU62-pCnupKuZfu8I9K5jiBd9MJzSFu7dRGzftQNx6LPQTc7mLgmnh_C-cJtFE91taAgnvFQ7n-bWE_4ojlf6iZUf0YgjvRlvM0ndJExZHITE5lbvKn-MrM3cthOBQ2jiT8M0YZ5Jj6k9c8Nc2FJaC--1wNevSgia0MFAdqSA3-xmz2a0-_gk9-XkTsoldDlOU0Mg2J965KPI9Fjvn7RL6szIni9lz0lZc5rWEjE31kPGL5pcR9fcggY_t-i8gUaqvomuHDrKxi30owcp9kCK5zV2IMU-SHEPUjyAFG-AFA8gfYY7iGIDUQwAww6iuKlwD9Hb6Oj1q8mLg8C1_whknPEkiDMaxjDDpCQhWVWyihPOeaIiAT5_QWnKFVgcWRUV51UoCCWqEKEsU05IwQpF7qCtuqnVNsJUZqyIpGK8VJRWKY9YSYsoJKUuZ5iWY0S695tLVxtft2g5zv-m2zEK-l-d2Now_zj_KajunKc-7vSbw3yvN_FErZr2NDdMCbCycTRGd63ie4mEwIKKR8m9C97YfXR1-B8-QFvLRasegq-9LB4Z2P4CgiDmQQ |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+vaccination+in+chronic+inflammatory+arthritis+undergoing+immunosuppressive+treatments%3A+temporal+trend+and+factors+of+adherence&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Quartuccio%2C+Luca&rft.au=Zabotti%2C+Alen&rft.au=Gallo%2C+Tolinda&rft.au=De+Vita%2C+Salvatore&rft.date=2021-05-14&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=60&rft.issue=5&rft.spage=2456&rft.epage=2460&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa454&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keaa454 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |